Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Olana Tansley-Hancock"'
Autor:
Gareth O. Griffiths, Richard FitzGerald, Thomas Jaki, Andrea Corkhill, Helen Reynolds, Sean Ewings, Susannah Condie, Emma Tilt, Lucy Johnson, Mike Radford, Catherine Simpson, Geoffrey Saunders, Sara Yeats, Pavel Mozgunov, Olana Tansley-Hancock, Karen Martin, Nichola Downs, Izabela Eberhart, Jonathan W. B. Martin, Cristiana Goncalves, Anna Song, Tom Fletcher, Kelly Byrne, David G. Lalloo, Andrew Owen, Michael Jacobs, Lauren Walker, Rebecca Lyon, Christie Woods, Jennifer Gibney, Justin Chiong, Nomathemba Chandiwana, Shevin Jacob, Mohammed Lamorde, Catherine Orrell, Munir Pirmohamed, Saye Khoo, on behalf of the AGILE investigators
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-5 (2021)
Abstract Background There is an urgent unmet clinical need for the identification of novel therapeutics for the treatment of COVID-19. A number of COVID-19 late phase trial platforms have been developed to investigate (often repurposed) drugs both in
Externí odkaz:
https://doaj.org/article/24657c03deb0425d9ec6d713b1197217
Autor:
Kim Mallard, William Greenhalf, Lauren Walker, Susannah Condie, Ellice Marwood, Michael Jacobs, Tom Fletcher, Gareth Griffiths, Geoffrey Saunders, Sean Ewings, Victoria Shaw, Richard Fitzgerald, Kerensa Thorne, Olana Tansley-Hancock, Andrew Owen, Lucy Johnson, Sara Yeats, David G. Lalloo, Wendy Painter, Helen Reynolds, Henry Pertinez, Thomas Jaki, Christie Woods, Keira Fines, Emma Wrixon, Colin Hale, Andrea Corkhill, Katie Bullock, Mike Radford, Emily R. Adams, Nichola Downs, Saye Khoo, Justin Chiong, Wayne Holman, Rebecca Lyon, Pavel Mozgunov, Marcin D Bula, Jennifer L Gibney
Publikováno v:
The Journal of antimicrobial chemotherapy
Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in participants with early symptomatic infection. Methods We undertook a dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a5576a4da8769d3c6064bde32dbfec8
https://eprints.soton.ac.uk/476394/
https://eprints.soton.ac.uk/476394/
Autor:
Kerensa Thorne, Andrew Owen, Justin Chiong, Thomas Jaki, Michael Jacobs, Gareth Griffiths, Sara Yeats, Tom Fletcher, Keira Fines, Susannah Condie, Geoffrey Saunders, Kim Mallard, Colin Hale, Jennifer L Gibney, Mike Radford, Nichola Downs, Olana Tansley-Hancock, Pavel Mozgunov, Marcin D Bula, Andrea Corkhill, Katie Bullock, Wendy Painter, Christie Woods, Victoria Shaw, William Greenhalf, Lauren Walker, David G. Lalloo, Wayne Holman, Richard Fitzgerald, Rebecca Lyon, Lucy Johnson, Henry Pertinez, Ellice Marwood, Sean Ewings, Emma Wrixon, Saye Khoo, Emily R. Adams, Helen Reynolds
BackgroundAGILE is a phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in participants with early symptomatic infection.MethodsWe undertook a dose-es
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d711f718d23a69bca351a8f58d141333
https://doi.org/10.1101/2021.05.03.21256309
https://doi.org/10.1101/2021.05.03.21256309